Purdue Pharma's Oxycontin reformulated to thwart abusers; U.S. Marshals seize misbranded Beehive products;

> A reformulated controlled-release Oxycontin, intended to prevent the opioid medication from being cut, broken, chewed, crushed or dissolved to release medication earlier than planned, has been approved by the FDA. Announcement

> The FDA sent U.S. Marshals to Beehive Botanicals in Haywood, WI, to seize misbranded and unapproved new drugs comprising consumer creams, capsules, tablets, gum, throat spray, and shampoos. Release

> Vaccine-maker Sanofi Pasteur is expanding its use of the Pertinence Suite Manufacturing Operations Management (MOM) software solution of Intercim, to European locations and North American sites. Release

> The U.K.-based Chemical Business Association has launched the Security Code, which requires a five-stage risk assessment, as part of its Responsible Care program. Release

> The Massachusetts Life Sciences Center has granted Worcester Polytechnic Institute $6.6 to build an 80,000-square-foot life sciences facility that will include a biomanufacturing education and training. Article

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.